Drugs that contain Liraglutide Recombinant

1. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(a month ago)

CN1951965A NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN100569798C NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1740198A NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1232470A NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1271086C NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1951965B NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1882356B NOVO For The Production And Used In The Injection Device Is The Best Peptide Formulations Containing Propylene Glycol
Nov, 2024

(2 years from now)

CN1882356A NOVO In The Production And Injection Device Is The Best Peptide Formulation Contains Propylene Glycol
Nov, 2024

(2 years from now)

IN257402B NOVO Propylene Glycolcontaining Peptide Formulations
Nov, 2024

(2 years from now)

IN200602771P1 NOVO Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP1840134A3 NOVO Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775B1 NOVO Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1840134B1 NOVO Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1840134A2 NOVO Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775A1 NOVO Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1060191A1 NOVO Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1062240A1 NOVO N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061946A1 NOVO Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1060191B1 NOVO Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1061946B1 NOVO Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1062240B1 NOVO N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061947B1 NOVO Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP1061947A1 NOVO Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP944648B1 NOVO Glp-1 Derivatives
Aug, 2022

(a month ago)

EP944648A1 NOVO Glp-1 Derivatives
Aug, 2022

(a month ago)

EP1687019A2 NOVO Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP1687019B1 NOVO Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP3300721A1 NOVO Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP3300721B1 NOVO Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1 Dec, 2022

(2 months from now)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs Feb, 2023

(4 months from now)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly Jun, 2023

(8 months from now)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly Dec, 2023

(1 year, 2 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly Nov, 2024

(2 years from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display Oct, 2025

(3 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Feb, 2026

(3 years from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display Apr, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism Jul, 2026

(3 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism Jul, 2026

(3 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen Aug, 2026

(3 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jan, 2027

(4 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jan, 2027

(4 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jan, 2027

(4 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen Feb, 2027

(4 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display Feb, 2027

(4 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display Aug, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism Sep, 2027

(4 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism Mar, 2028

(5 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen Feb, 2032

(9 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen Aug, 2032

(9 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions Jan, 2037

(14 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions Jul, 2037

(14 years from now)

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

2. Drug name - VICTOZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(a month ago)

US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

CN1951965A NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN100569798C NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1740198A NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1232470A NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1271086C NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1951965B NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1882356B NOVO NORDISK INC For The Production And Used In The Injection Device Is The Best Peptide Formulations Containing Propylene Glycol
Nov, 2024

(2 years from now)

CN1882356A NOVO NORDISK INC In The Production And Injection Device Is The Best Peptide Formulation Contains Propylene Glycol
Nov, 2024

(2 years from now)

IN257402B NOVO NORDISK INC Propylene Glycolcontaining Peptide Formulations
Nov, 2024

(2 years from now)

IN200602771P1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP1840134A3 NOVO NORDISK INC Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775B1 NOVO NORDISK INC Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1840134B1 NOVO NORDISK INC Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1840134A2 NOVO NORDISK INC Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775A1 NOVO NORDISK INC Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1060191A1 NOVO NORDISK INC Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1062240A1 NOVO NORDISK INC N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061946A1 NOVO NORDISK INC Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1060191B1 NOVO NORDISK INC Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1061946B1 NOVO NORDISK INC Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1062240B1 NOVO NORDISK INC N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061947B1 NOVO NORDISK INC Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP1061947A1 NOVO NORDISK INC Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP944648B1 NOVO NORDISK INC Glp-1 Derivatives
Aug, 2022

(a month ago)

EP944648A1 NOVO NORDISK INC Glp-1 Derivatives
Aug, 2022

(a month ago)

EP1687019A2 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP1687019B1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP3300721A1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP3300721B1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1 Dec, 2022

(2 months from now)

US6268343

(Pediatric)

NOVO NORDISK INC Derivatives of GLP-1 analogs Feb, 2023

(4 months from now)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly Jun, 2023

(8 months from now)

US8579869

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly Dec, 2023

(1 year, 2 months from now)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly Nov, 2024

(2 years from now)

US8114833

(Pediatric)

NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Feb, 2026

(3 years from now)

US9265893 NOVO NORDISK INC Injection button Sep, 2032

(9 years from now)

US9265893

(Pediatric)

NOVO NORDISK INC Injection button Mar, 2033

(10 years from now)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions Jan, 2037

(14 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions Jul, 2037

(14 years from now)

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.